Your session is about to expire
← Back to Search
Behavioral Intervention
NRF for Traumatic Brain Injury
N/A
Recruiting
Led By Maria Kajankova, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at year 3
Awards & highlights
No Placebo-Only Group
Summary
This trial will test a new therapy to see if it can help reduce criminal behavior in people with brain injury.
Who is the study for?
This trial is for English-speaking adults over 18 with a history of brain injury, who are returning to specific counties in the U.S. within six months of release from incarceration. They must show significant cognitive impairment on certain tests.
What is being tested?
The study is testing NeuroResource Facilitation (NRF), an innovative approach aimed at reducing repeat offenses among individuals with traumatic brain injuries by providing them with specialized support and resources.
What are the potential side effects?
Since NRF involves supportive services rather than medical or pharmaceutical interventions, traditional side effects are not applicable. However, participants may experience varying degrees of emotional or psychological impact.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at year 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at year 3
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Recidivism
Secondary study objectives
Date Committed
Date of Reception
Date of entry into Department of Corrections
+13 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: NeuroResource FacilitationActive Control1 Intervention
As part of the NRF intervention group, participants will receive specialized care management, both in prison and after the participant goes home. While in the State Correctional Institution (SCI), participants will meet weekly to monthly depending on resource needs, and how close participant is to release with a NeuroResource Facilitator in person who will help participants to understand more about their challenges. Participants may also be referred to a group run by the Facilitator in conjunction with staff from the prison. The facilitator will also tell the participant about resources that are available to help after the participant's release and help participants get connected to them.
Group II: Standard of CareActive Control1 Intervention
As part of the SoC, participants will receive the re-entry services normally receive if not in the study including (but not limited to) Treatment Services, Educational and Vocational Training, Mental Health Management, Reentry and Transitional Services, Population Management and Community Corrections.
Find a Location
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
904 Previous Clinical Trials
541,040 Total Patients Enrolled
Brain Injury Association of PennsylvaniaUNKNOWN
Maria Kajankova, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
2 Previous Clinical Trials
187 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am younger than 18 years old.I am 18 years old or older.I was released from incarceration within the last 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: NeuroResource Facilitation
- Group 2: Standard of Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger